Adrian planning commissioners support housing development plan at former Bixby Hospital site
ADRIAN — The fate of a planned unit development in Adrian to transform the former ProMedica Bixby Hospital site into a residential housing community will go before the Adrian City Commission at next week's Monday, March 17 meeting on St. Patrick's Day.
The city commission meets in downtown Adrian at Adrian City Chambers, 159 E. Maumee St., unless otherwise noted. Regular meetings start at 6 p.m.
The commission will be tasked with reviewing a planned unit development (PUD) proposal that seeks to construct a housing community of 63 for-rent, market rate single-family homes, varying from one- to two-bedrooms. The proposed residential structures are not to be considered as low-income housing, it was clarified during last week's monthly meeting of the Adrian planning commission, which met March 4 to inspect the project's final development plan.
The former Bixby Hospital was at 818 Riverside Ave., since June 1957 and across from the Adrian High School campus. It had been vacant since 2020 when it was shuttered and replaced by ProMedica Charles and Virginia Hickman Hospital in Adrian Township.
Initial talks about tearing down Bixby Hospital and constructing rental houses on the property began in January 2024 when real estate developer Michael Collier told the city commission, he secured a contract with ProMedica to redevelop the property and tear down the hospital.
It took most of 2024, but in early December — and after a handful of meetings between Collier, his business partner Scott Gibson, and the planning commission — demolition started on the hospital. Bixby Hospital has since nearly been completely razed with demolition crews taking the building down in sections to offset noise for nearby residents.
From December 2024: Demolition plans announced by ProMedica for vacant Bixby Hospital; demo work starts Dec. 5
Flint-based RJ Industrial Recycling is contracted with ProMedica and Collier and Gibson — who are partners in the real estate development firm — Collier-Gibson, a firm that focuses on creative adaptive reuse and ground-up development projects in the United States with a current concentration in the Midwest, to complete the demolition.
Collier-Gibson specializes in hotels, multifamily units, office, industrial, retail, restaurants and self-storage projects.
Being the third time the Adrian planning commissioners requested Collier-Gibson to come back with an amended development plan, it didn't take long at last week's meeting for the commissioners to give their final approval of the housing project.
The PUD was unanimously approved by the planning commission in a 5-0 vote, albeit with two members absent from the meeting in Chad Johnson and Brian Watson.
The approval came with a few minor contingencies that need to be addressed going forward:
Providing the planning commission with a lighting diagram of the housing community.
Providing a complete PUD development schedule/timeline.
Providing a report in good terms about the project from the Lenawee County Drain Commission.
Providing a notice of responsibility that the property owner will be responsible for all common grounds maintenance.
Beaubien Companies Inc., in Adrian will be contracted for landscaping and maintenance work at the community to 'create common maintenance and continuity to the site,' Gibson explained.
Any action taken by the planning commission is in the form of a recommendation to the Adrian City Commission, which has the final review and say of whether a project is ready for approval or needs to be sent back for additional work.
'As we have discussed time after time after time, this (housing proposal) addresses this to a great extent,' Planning Commission Chairman Mike Jacobitz said of the proposal providing housing options in Adrian. 'There's always the possibility that if that land lies fallow, who knows what becomes of it. Here's something that we have some control over and addresses an identified need.'
The contingencies that were included in the final approval are 'relatively minor,' Jacobitz told The Daily Telegram, and have nothing to do with the housing concept itself.
The Bixby Hospital property is currently zoned office/service. With an approval from the city commission at their March 17 meeting, it will be updated to planned unit development. PUD is almost an 18-month process for approval, Jacobitz said. A planned unit development requires the approval of both the planning commission and the city commission as it changes the ordinance and the zoning of a particular property.
'I like the plan. I think it's good. Obviously, we need housing in the city of Adrian so I'm very pleased to see you're moving forward with it,' Adrian City Commissioner and Planning Commissioner Gordon Gauss said during last week's meeting.
Support local news and subscribe: For all the latest local developments, breaking news, and high school and college sports content.
A handful of neighboring residents adjacent to the Bixby Hospital property approached the planning commission last week and raised a variety of concerns about the project including landscaping, how the development doesn't address missing middle housing in Adrian, traffic, population and property maintenance.
Gibson said he expects there to be at least 150 people residing within the residential community. Ideally, and what makes the most sense, he added, is constructing all units at the same time.
'Presently, we are contemplating doing it in one shot,' Gibson said when asked by the planning commission if construction on the development will be completed all at once or in stages. 'It is possible that it could be done in two phases. We've looked at doing maybe 24 units and leasing those and then doing the balance, but that hasn't been finalized. We're entertaining both scenarios at present.'
Wherever visual barriers are needed, those are being added, Gibson said addressing one of the landscaping concerns. More vegetation will be added to the site to ensure it is attractive and an enhancement.
Julie Jungwirth, an Adrian resident on McKenzie Street, provided the most feedback for the planning commission at last week's meeting, saying she was 'at a loss' because of the lack of an open house, information or presentation about the housing development at the Bixby site.
'I don't think enough was done to present this,' she told the planning commission.
From April 2024: Plans to build rental housing on former Bixby Hospital site continue
According to Michigan statute, information about zoning changes will be notified to those who are within 300 feet around the parcel. Information about planning commission meetings, topics of discussion and presentation are published in a newspaper of regular circulation — like The Daily Telegram — and on the city of Adrian's website, adriancity.com.
Discussions of the Bixby redevelopment have been taking place at planning commission meetings for more than six months, Gauss responded. Over those six months, there have been at least three presentations by Collier-Gibson on the development, which the planning commission has requested additional information and adjustments to the plan nearly each time.
'This is not any big secret,' Gauss said. 'People have been asking when the hospital was going to come down, what was going to go there, and it's been clearly explained, but yet we are still getting questions like yours. But to say we're not being transparent; that's just not the case.'
Now that the hospital has been leveled, residents should expect continued noise from concrete grinding, material sorting and hauling truck traffic, ProMedica said in a statement. Road closures should not be anticipated during the process.
Demolition crews from RJ Industrial Recycling told The Daily Telegram they expect to be on pace with ProMedica's initial schedule of having all demo and debris removal activities completed by April. Briskey Brothers Construction from Tecumseh also is on site at the former hospital working alongside RJ Industrial Recycling to haul away scrap concrete.
— Contact reporter Brad Heineman at bheineman@lenconnect.com or follow him on X, formerly Twitter: @LenaweeHeineman.
This article originally appeared on The Daily Telegram: Adrian planning commission supports development at Bixby Hospital site
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
an hour ago
- Boston Globe
Will Trump's policies kill Massachusetts' life sciences leadership?
Advertisement Although the industry is centered in eastern Massachusetts, there's a statewide benefit from all the tax dollars those businesses and workers pay. Get The Gavel A weekly SCOTUS explainer newsletter by columnist Kimberly Atkins Stohr. Enter Email Sign Up In all, Massachusetts organizations — including universities, research institutes, and hospitals — received $3.5 billion in funding from the National Institutes of Health. Massachusetts-headquartered companies raised $3.26 billion in venture capital funding. Among all drugs in the development pipeline in the United States, 15 percent were being made by companies headquartered in Massachusetts. But actions taken by President Trump and his administration — cutting funding for scientific research and universities, flirting with tariffs, fanning skepticism about vaccines — threaten to devastate the ecosystem. Today, the industry is at a precipice, and uncertainty abounds. Some companies are already feeling the pinch of terminated federal grants, while others are anxious about what might come. Taken together, Trump's policies could force some companies and scientists to take their money, talents, and products overseas. Advertisement Christopher Locher, CEO of Lowell-based Versatope Therapeutics, which develops a platform to deliver vaccines and therapeutics, said he worries the Greater Boston life sciences ecosystem is 'being flushed down the toilet.' For example, Trump is Trump's funding cuts are already having a large impact on some local companies. Part of the problem is the Trump administration isn't only cutting funding, but it's picking which technologies to fund — in some cases apparently based on politics more than science. Take flu vaccines. The Trump administration recently announced a $500 million campaign to fund the development of a universal flu vaccine, which doesn't require annual updates, using technology being worked on But simultaneously, he cut funding for other work on a universal flu vaccine. Versatope Therapeutics got $14 million in NIH funding and spent five years developing a universal flu vaccine. It had approval from the US Food and Drug Administration to begin clinical trials when Trump terminated the contract's remaining $8 million, with the reason given being 'convenience,' Locher said. Trump also Advertisement Company executives say decisions by Trump officials to disinvest in vaccine-related technology — and concerns about whether government will approve new technology — means it's nearly impossible to find private investment funding to replace lost federal dollars. 'We're faced with bankruptcy in the very near future,' Locher said. Ironically, given Trump's stated commitment to bringing businesses back to the United States, one potential option Locher is eyeing is opening a subsidiary abroad. Conducting clinical trials would be cheaper in another country, whether in Europe, Australia, or China, Locher said, and some countries are offering financial incentives to American companies to relocate. Companies also face a potential workforce brain drain. There have been MassBio officials said China has less rigorous — but faster — safety and research protocols than the US. Australia allows a faster timeline for clinical trials. If regulatory approval of medicines is held up because the FDA is understaffed, companies may seek European regulatory approval instead. The loss of talent to foreign countries will be compounded if the pipeline of local university graduates dries up. One draw for life sciences companies to Boston/Cambridge is the presence of elite schools like Harvard and MIT, with their potential for faculty collaboration and skilled graduates. Advertisement Trump is trying to Chip Clark, CEO at Vibrant Biomedicines in Cambridge, said cuts to university research funding both 'shrink the pipeline of great ideas' that form the basis for many biotech startups and translate to fewer available scientists. Clark said the administration's policies 'seem like a deliberate attempt to try to cede scientific leadership to Europe and Japan and Korea and China. ... They will be delighted to capitalize on our talent, technology, and investment capital to make their robust biotech sectors grow and ultimately compete successfully against the US industry,' he said. Don Ingber, founding director of the Wyss Institute for Biologically Inspired Engineering at Harvard University, said he has postdocs with US visas applying for jobs in Europe, and others who were accepted to work at Harvard but are going elsewhere. 'The fact that places like Harvard and MIT and American universities are magnets for the best and brightest from around the world is what's driven our technology economy and certainly the Boston/Cambridge ecosystem,' Ingber said. 'With this uncertainty, I fear we'll lose a generation.' Ingber, who was forced to stop work on two government-funded projects on drugs designed to prevent injury from radiation exposure, compared administration policies to 'eating seed corn' needed to grow crops. Advertisement Trump's vendetta will undermine one of the most vibrant state economies in the country and set back American science by years. And it's not just eastern Massachusetts that will pay a price; the entire country will. As Ingber noted, it might take years to see the impact of medicines or technologies that aren't developed because of these shortsighted cuts. Editorials represent the views of the Boston Globe Editorial Board. Follow us
Business Insider
an hour ago
- Business Insider
I'm a Gen Zer who landed a 6-figure job at Morgan Stanley before graduation. Here's what the process was like — and why you should refresh a surprisingly important part of your résumé.
This as-told-to essay is based on a conversation with Sara Thomas, 22, a 2025 graduate from the University of Chicago and incoming investment banking analyst at Morgan Stanley. Business Insider's recent " Path to Wall Street" series highlighted how finance careers continue to attract young talent, despite the industry's long hours and demanding entry-level roles. Entry-level bankers typically earn about $110,000 a year, not including bonuses. This interview has been edited for length and clarity. I had barely decided on banking as a career choice when I had to start preparing for interviews. My experience was similar to most stories I've heard about the banking world: the recruiting process starts early. Before submitting my internship applications, I spoke to about five people at each major bank — mostly recent UChicago grads and people the university's career advancement program connected me with — so they would recognize my name when they saw my résumé. Cold LinkedIn messaging didn't work very well for me. Those introductions are often necessary to get an interview. At most banks, I interviewed for multiple rounds, including calls focused on my personality and technical skills and a two-hour " super day." The whole process lasted about two weeks. Then, by the spring of my sophomore year, I was done. I landed an internship at Morgan Stanley, and I knew my full-time job would be set as long as I got a return offer. My prior internships had been at Bain Capital and the Chicago-based firm Ariel Investments. The only other career trajectory I considered in college was academia. I studied economics and considered getting involved with economics research, but I realized it wasn't for me. I just work better in a faster-paced finance environment. In my free time at school, I tried to focus on clubs and internships that would keep me close to startups and entrepreneurship, so I joined a venture capital fund on campus. I was also involved in a campus group for women and minorities interested in finance and investing. Those opportunities really helped me build my industry chops. I would tell any college student hoping to land a Wall Street or Silicon Valley job: be decisive. Even if investment banking or consulting isn't your lifelong passion, plan to commit to a career path sooner rather than later, so that you can give yourself the most amount of time to prepare, network, and do really well in the interviews. And, for the application process, students need to be careful with what they put on their résumé — recruiters pay a lot of attention to the "skills and interests" section at the bottom. Don't say that you're a mountain climber if you have never climbed a mountain, because people will ask you about your hobbies, and you need to be able to genuinely talk about them. Of course, your credentials matter, but I've found that recruiters are most interested in meeting well-rounded people. Job applications and postgrad life make me anxious sometimes. I've leaned on my friends a lot: Some aren't going into finance, others have gone through recruiting alongside me. I'm also grateful for my family — my Morgan Stanley role will be in San Francisco, and it will be the first time I've moved far from home, since I grew up in Chicago. Exercise has always been a coping strategy for me, too. I'm trying to build healthy habits and make sure I don't isolate myself. Those are the main ways I'm dealing with stress. Long, long term, my biggest goal is to be able to work for myself in some way. That could mean working at a big company that gives me a lot of autonomy to make decisions or starting my own company, if I am brave enough to do that. For now, I'm excited to keep building my career and learning from my coworkers. Having engaging conversations with people you've never met can be the most challenging part of the finance industry, but it's also the most rewarding.
Axios
3 hours ago
- Axios
Exclusive: Logistics safety startup Voxel raises $44M Series B
Logistics safety startup Voxel closed a $44 million Series B led by NewRoad Capital Partners, CEO Vernon O'Donnell tells Axios Pro exclusively. Why it matters: It gives San Franscisco-based Voxel three years of runway to reach breakeven or accelerate growth and raise again, its CEO says. How it works: The software integrates into existing security cameras, using AI to identify in real time — and increasingly predict — workplace hazards. Such scenarios include shelf integrity, forklift operation, employee movements or aisle spills that could present safety concerns. While worker safety is the core business case, the software's capabilities extend to productivity and efficiency, O'Donnell says. State of play: Nearly 3 million people die in workplace incidents each year globally, according to the International Labour Organization. Worker compensation, increased insurance premiums and a toll on morale stem from such incidents, hitting companies' annual bottom lines. Zoom in: Voxel counts 14 Fortune 500 customers, six of which have signed contracts in the last 120 days, the CEO says. One Fortune 50 customer changed the entire loading and unloading process for a more than 1 million-square-foot distribution center based on Voxel's recommendations, he says. Adopters across various sectors include Albertsons, Dick's Sporting Goods, Americold, AGI, the Port of Virginia and Berry Global. What they're saying: "We're seeing ... a hard ROI: reduction in worker's comp claims, reduction in OSHA fines, reduction in lost days," O'Donnell says. "Their speed of using AI to then be able to classify, 'is this an unsafe act or not?' and then alert leadership to take action — that's what really sold us," said Chris Sultemeier, NewRoad Capital Partners operating partner and former Walmart EVP of logistics. Friction point: Union workers have sometimes objected to video monitoring they consider invasive.
